Similarly, the second-generation FLT3 inhibitors quizartinib and gilteritinib have been shown to improve OS when added to intensive chemotherapy [29] or as monotherapy in r/r FLT3-mutant AML as compared to standard salvage chemotherapy [30, 31]. Here, FLT3 is linked to acute myeloid leukemia.